A carregar...
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947217/ https://ncbi.nlm.nih.gov/pubmed/33694304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.723 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|